Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    aTyr Pharma, Inc. (LIFE)

    Price:

    1.90 USD

    ( + 0.05 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    LIFE
    Name
    aTyr Pharma, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    1.900
    Market Cap
    131.121M
    Enterprise value
    117.447M
    Currency
    USD
    Ceo
    Sanjay S. Shukla
    Full Time Employees
    56
    Ipo Date
    2015-05-07
    City
    San Diego
    Address
    3545 John Hopkins Court

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    60.756B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.556B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.375B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -1.352
    P/S
    0
    P/B
    1.204
    Debt/Equity
    0.169
    EV/FCF
    -1.679
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.739
    Debt/assets
    0.125
    FUNDAMENTALS
    Net debt/ebidta
    0.066
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.001
    Capex to revenue
    0
    Capex to depreciation
    0.042
    Return on tangible assets
    -0.656
    Debt to market cap
    0.129
    Piotroski Score
    3.000
    FUNDAMENTALS
    PEG
    -2.218
    P/CF
    26.094
    P/FCF
    18.369
    RoA %
    -72.985
    RoIC %
    -80.208
    Gross Profit Margin %
    58.548
    Quick Ratio
    5.633
    Current Ratio
    5.633
    Net Profit Margin %
    1.588k
    Net-Net
    0.597
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.618
    Revenue per share
    0
    Net income per share
    -0.739
    Operating cash flow per share
    -0.617
    Free cash flow per share
    -0.618
    Cash per share
    0.892
    Book value per share
    0.828
    Tangible book value per share
    0.828
    Shareholders equity per share
    0.831
    Interest debt per share
    0.141
    TECHNICAL
    52 weeks high
    2.450
    52 weeks low
    1.080
    Current trading session High
    1.950
    Current trading session Low
    1.820
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.833
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.410
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.040
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.154
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.409

    No data to display

    logo

    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.292
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.209
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -7.975
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.250
    DESCRIPTION

    aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

    NEWS
    https://images.financialmodelingprep.com/news/osisko-development-announces-c30-million-bought-deal-life-offering-of-national-20251008.png
    Osisko Development Announces C$30 Million Bought Deal LIFE Offering of National and BC Flow-Through Shares

    globenewswire.com

    2025-10-08 17:55:00

    NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") is pleased to announce that it has entered into an agreement with National Bank Financial Inc., BMO Capital Markets and RBC Capital Markets, acting as co-lead underwriters and co-bookrunners (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase (or arrange for substituted purchasers to purchase), on a "bought deal" private placement basis pursuant to the LIFE Exemption (as defined herein), two tranches of flow-through shares for aggregate gross proceeds of C$30,010,020 (the "Offering"), as follows: National Flow-Through Shares: 2,990,000 common shares of the Company (the "FT Shares") that will qualify as "flow-through shares" within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the "Tax Act") at a price of C$6.69 per FT Share for gross proceeds of C$20,003,100; and British Columbia Flow-Through Shares: 1,444,000 common shares of the Company to certain eligible British Columbia resident subscribers (the "BC FT Shares", and together with the FT Shares, the "Flow-Through Shares") that will qualify as "flow-through shares" within the meaning of subsection 66(15) of the Tax Act at a price of C$6.93 per BC FT Share for gross proceeds of C$10,006,920. The Company will use an amount equal to the aggregate gross proceeds of the Offering to incur eligible "Canadian exploration expenses" that will qualify as (i) "flow-through mining expenditures" within the meaning of the Tax Act, and (ii) in respect of the BC FT Shares purchased by eligible British Columbia purchasers, "BC flow-through mining expenditures" that meet the criteria set forth in subsection 4.721(1) of the Income Tax Act (British Columbia), in respect of the exploration activities on the Company's properties in British Columbia (the "Qualifying Expenditures").

    https://images.financialmodelingprep.com/news/mcfarlane-lake-announces-filing-of-amended-and-restated-life-20251007.jpeg
    McFarlane Lake Announces Filing of Amended and Restated LIFE Offering Document

    newsfilecorp.com

    2025-10-07 21:30:00

    Toronto, Ontario--(Newsfile Corp. - October 7, 2025) - McFarlane Lake Mining Limited (CSE: MLM) (OTCQB: MLMLF) ("McFarlane Lake" or the "Company"), a Canadian gold exploration and development company, announces that, further to its news release dated September 22, 2025 regarding its offering (the "Offering") under the listed issuer financing exemption pursuant to Part 5A of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935, the Company has filed an amended and restated offering document on SEDAR+ to reflect recent developments. These developments include the completion on September 29, 2025 of the first tranche of the Offering, the closing of a US$15 million bridge financing, and the completion of the acquisition of the Juby Project and an interest in the Knight Properties from Aris Mining Holdings Corp. ("AMHC") pursuant to the asset purchase agreement dated July 7, 2025, among the Company, Aris Mining Corporation, and AMHC.

    https://images.financialmodelingprep.com/news/surge-battery-metals-announces-clarification-on-previously-announced-nonbrokered-20251007.jpeg
    Surge Battery Metals Announces Clarification on Previously Announced Non-Brokered LIFE Offering

    newsfilecorp.com

    2025-10-07 20:58:45

    West Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Surge Battery Metals Inc. (TSXV: NILI) (OTCQX: NILIF) (FSE: DJ5) (the "Company" or "Surge")  wishes to make a clarification with respect to its previously announced non-brokered private placement offering (the "LIFE Offering") of up to 20,000,000 units (the "Offered Units") at a price of $0.25 per Offered Unit for aggregate gross proceeds of $5,000,000, pursuant to the listed issuer financing exemption available under Part 5A of National Instrument 45-106 - Prospectus Exemptions. Each Offered Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").

    https://images.financialmodelingprep.com/news/allied-critical-metals-announces-upsized-1625-million-life-offering-20251007.jpeg
    Allied Critical Metals Announces Upsized $16.25 Million LIFE Offering

    newsfilecorp.com

    2025-10-07 18:04:00

    Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Allied Critical Metals Inc. (CSE: ACM) (OTCQB: ACMIF) (FSE: 0VJ0) ("Allied" or the "Company"), is pleased to announce that as a result of strong investor demand, the Company increased the size of its previously announced non-brokered private placement offering (the "Offering") to raise gross proceeds of up to $16,250,000 by issuing up to 27,083,333 common shares of the Company (the "Shares" and, each, a "Share") at a price of $0.60 per Share. The Shares will be offered to purchasers pursuant to the Listed Issuer Financing Exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106") to purchasers resident in Canada, except Quebec, and certain jurisdictions outside of Canada.

    https://images.financialmodelingprep.com/news/retransmission-unidoc-announces-life-offering-20251007.jpg
    RETRANSMISSION UniDoc Announces LIFE Offering

    accessnewswire.com

    2025-10-07 10:35:00

    THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 7, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") is pleased to announce a non-brokered private placement LIFE offering (the "Offering") for total gross proceeds of up to $1,500,000, consisting of up to 10,000,000 units of the Company (each, a "Unit") at a price of $0.15 per Unit. Each Unit will consist of one common share in the capital of the Company and one transferrable common share purchase warrant (a "Warrant").

    https://images.financialmodelingprep.com/news/f3-announces-closing-of-c20-million-bought-deal-life-20251003.jpeg
    F3 Announces Closing of C$20 Million Bought Deal LIFE Private Placement

    newsfilecorp.com

    2025-10-03 10:00:00

    Kelowna, British Columbia--(Newsfile Corp. - October 3, 2025) - F3 Uranium Corp. (TSXV: FUU) (OTCQB: FUUFF) (FSE: GL7) ("F3" or the "Company") is pleased to announce the closing of its previously announced "bought deal" private placement (the "Offering") for aggregate gross proceeds of C$20,000,000, which includes the exercise in full of the Underwriters' (as defined herein) over-allotment option. Pursuant to the Offering, the Company sold the following: 25,000,000 units of the Company (each, a "Unit") at a price of C$0.20 per Unit; 14,814,815 non-critical mineral flow-through units of the Company sold to charitable purchasers (the "NFT Units") at a price of C$0.27 per NFT Unit; 16,666,667 federal flow-through units of the Company sold to charitable purchasers (the "FFT Units") at a price of C$0.30 per FFT Unit; and 18,181,818 Saskatchewan flow-through units of the Company sold to charitable purchasers (the "SFT Units", and together with the NFT Units and FFT Units, the "FT Units") at a price of C$0.33 per SFT Unit.

    https://images.financialmodelingprep.com/news/midnight-sun-mining-increases-bought-deal-life-offering-to-20251003.jpeg
    Midnight Sun Mining increases 'bought deal' LIFE offering to C$17.5M

    proactiveinvestors.com

    2025-10-03 09:20:02

    Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) reported that it has amended the terms of its previously announced “bought deal” Listed Issuer Financing Exemption (LIFE) offering and private placement financing to increase the size of the offering to C$17.5 million.   The exploration company said net proceeds from the sale will be used by for advancing exploration across the company's Zambian exploration projects and for working capital and general corporate purposes.

    https://images.financialmodelingprep.com/news/midnight-sun-announces-upsize-to-previously-announced-bought-deal-life-20251003.jpg
    Midnight Sun Announces Upsize to Previously Announced “Bought Deal” LIFE Offering and Private Placement of Units to C$17.5 Million

    globenewswire.com

    2025-10-03 08:38:00

    / NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Midnight Sun Mining Corp. (TSXV:MMA, OTC:MDNGF) (“Midnight Sun” or the “Company”) is pleased to announce that it has amended the terms of its previously announced “bought deal” LIFE offering and private placement financing to increase the size of the offering to C$17.5 million (the “Upsized Offering”). Under the terms of the Upsized Offering, Haywood Securities Inc. (“Haywood”), as lead underwriter and sole bookrunner, on its own behalf and on behalf of a syndicate of underwriters including Beacon Securities Limited, Red Cloud Securities Inc., and SCP Resource Finance LP (together with Haywood, the “Underwriters”), has agreed to purchase, on a "bought deal" basis, 12,963,000 units of the Company (the “Units”) at a price per Unit of C$1.35 (the “Issue Price”) for aggregate gross proceeds to the Company of C$17,500,050, to be issued and sold to eligible purchasers pursuant to: (i) private placement exemptions in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”) (the “Private Placement Exemptions”); and/or (ii) the ‘listed issuer financing exemption' under Part 5A of NI 45-106 and Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “LIFE Exemption”), in any combination thereof.

    https://images.financialmodelingprep.com/news/standard-uranium-announces-expansion-of-davidson-river-drill-program-and-20251003.jpeg
    Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering

    newsfilecorp.com

    2025-10-03 07:15:00

    Vancouver, British Columbia--(Newsfile Corp. - October 3, 2025) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce a significant expansion to the planned diamond drill program at its flagship Davidson River project ("Davidson River" or the "Project") in the southwest Athabasca Basin region, northern Saskatchewan (Figure 1).

    https://images.financialmodelingprep.com/news/nord-precious-metals-announces-amendment-to-its-nonbrokered-life-20251003.jpg
    Nord Precious Metals Announces Amendment to Its Non-Brokered LIFE Financing

    newsfilecorp.com

    2025-10-02 20:27:56

    Coquitlam, British Columbia--(Newsfile Corp. - October 2, 2025) - Nord Precious Metals Mining Inc. (TSXV: NTH) (OTCQB: CCWOF) (FSE: 4T9B) (the "Company" or "Nord") further to the Company's news release dated September 15, 2025, the Company has amended its previously filed Listed Issuer Financing Exemption ("LIFE") Offering Document. The Company will now be raising 13,056,041 units at a price of $0.12 per share for gross proceeds of $1,566,724 through the LIFE Offering Document.

    https://images.financialmodelingprep.com/news/unidoc-announces-life-offering-20251002.jpg
    UniDoc Announces LIFE Offering

    accessnewswire.com

    2025-10-02 18:45:00

    THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 2, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") is pleased to announce a non-brokered private placement LIFE offering (the "Offering") for total gross proceeds of up to $1,500,000, consisting of up to 10,000,000 units of the Company (each, a "Unit") at a price of $0.15 per Unit. Each Unit will consist of one common share in the capital of the Company and one transferrable common share purchase warrant (a "Warrant").

    https://images.financialmodelingprep.com/news/midnight-sun-mining-to-raise-c10m-in-bought-deal-20251002.jpeg
    Midnight Sun Mining to raise C$10M in 'bought deal' LIFE offering

    proactiveinvestors.com

    2025-10-02 16:46:13

    Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) announced that it has entered into an agreement with Haywood Securities, as lead underwriter and sole bookrunner, in which Midnight Sun will sell on a "bought deal" basis 7,408,000 company units, at a price of C$1.35 per unit, for total gross proceeds of C$10,000,800.  The exploration company said net proceeds from the sale will be used by for advancing exploration across the company's Zambian exploration projects and for working capital and general corporate purposes.

    https://images.financialmodelingprep.com/news/dolly-varden-silver-announces-30-million-boughtdeal-financing-20251001.jpeg
    Dolly Varden Silver Announces $30 Million Bought-Deal Financing

    globenewswire.com

    2025-10-01 16:20:00

    NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Dolly Varden Silver Corporation (TSXV: DV) (NYSE American: DVS) (FSE: DVQ) (the “Company” or “Dolly Varden”) is pleased to announce that it has entered into an agreement with Haywood Securities Inc., on its behalf and on behalf of Research Capital Corporation, as joint bookrunners and co-lead underwriters, and on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bough-deal basis, a combination of securities of the Company (“Offered Securities”) for aggregate gross proceeds to the Company of $30,034,000, consisting of: 2,300,000 common shares of the Company (“Common Shares”) at a price of $6.50 per Common Share, to be issued on a prospectus-exempt basis pursuant to the ‘listed issuer financing exemption' (“LIFE”) under applicable Canadian securities laws (the “LIFE Offering”); and 750,000 common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) that will be issued as part of a charity arrangement (each, a “CFT Share”) at a price of $9.42 per CFT Share, to be issued under the LIFE Offering; and 990,000 common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Tax Act (each, a “FT Share”) at a price of $8.10 per FT Share, to be issued on a prospectus exempt basis other than LIFE (the “Private Placement Offering”, and together with the LIFE Offering, the “Offerings”). The LIFE Offering will be a combination of Common Shares and CFT Shares for gross proceeds of $22,015,000, and together with the Private Placement Offering will result in aggregate gross proceeds to the Company of $30,034,000.

    https://images.financialmodelingprep.com/news/dolly-varden-silver-announces-30-million-boughtdeal-financing-20251001.jpeg
    Dolly Varden Silver Announces $30 Million Bought-Deal Financing

    newsfilecorp.com

    2025-10-01 16:00:00

    Vancouver, British Columbia--(Newsfile Corp. - October 1, 2025) - Dolly Varden Silver Corporation (TSXV: DV) (NYSE American: DVS) (FSE: DVQ) (the "Company" or "Dolly Varden") is pleased to announce that it has entered into an agreement with a syndicate of underwriters (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bough-deal basis, a combination of securities of the Company ("Offered Securities") for aggregate gross proceeds to the Company of $30,034,000, consisting of: 2,300,000 common shares of the Company ("Common Shares") at a price of $6.50 per Common Share, to be issued on a prospectus-exempt basis pursuant to the 'listed issuer financing exemption' ("LIFE") under applicable Canadian securities laws (the "LIFE Offering"); and 750,000 common shares of the Company that will qualify as "flow-through shares" within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the "Tax Act") that will be issued as part of a charity arrangement (each, a "CFT Share") at a price of $9.42 per CFT Share, to be issued under the LIFE Offering; and 990,000 common shares of the Company that will qualify as "flow-through shares" within the meaning of subsection 66(15) of the Tax Act (each, a "FT Share") at a price of $8.10 per FT Share, to be issued on a prospectus exempt basis other than LIFE (the "Private Placement Offering", and together with the LIFE Offering, the "Offerings"). The LIFE Offering will be a combination of Common Shares and CFT Shares for gross proceeds of $15,084,000, and together with the Private Placement Offering will result in aggregate gross proceeds to the Company of $30,034,000.

    https://images.financialmodelingprep.com/news/ethos-technologies-targets-ipo-amid-positive-insurance-offerings-20250930.jpg
    Ethos Technologies Targets IPO Amid Positive Insurance Offerings

    seekingalpha.com

    2025-09-30 14:59:29

    Ethos Technologies Inc. has filed for a $100 million IPO and provides a three-sided digital life insurance marketplace platform. LIFE is growing rapidly and profitably, with strong revenue, gross margin, and a recent swing to positive cash flow from operations. Risks include high revenue concentration among a few insurance carriers and agencies, and a dual-class share structure limiting public investor voting rights.

    https://images.financialmodelingprep.com/news/domestic-metals-announces-upsize-of-life-offeringof-units-20250930.png
    Domestic Metals Announces Upsize of LIFE Offering of Units

    globenewswire.com

    2025-09-30 07:30:00

    **NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES** VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Domestic Metals Corp. (the “Company” or “Domestic Metals”) - (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E) announces that, as a result of strong investor demand, the Company has increased the size of its previously announced non-brokered private placement pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), as amended and supplemented by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption”).